David Cohen

Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.

V. Backer, M. Braddock, Dave Singh, 2018, The Lancet. Respiratory medicine.

Benralizumab efficacy and safety in severe asthma: A randomized trial in Asia.

Shanping Jiang, Xiao-Li Zhu, V. Shih, 2024, Respiratory medicine.

Pharmacokinetics/pharmacodynamics of benralizumab in chronic rhinosinusitis with nasal polyps: Phase III, randomized, placebo-controlled OSTRO trial.

Joseph K. Han, C. Hopkins, Claus Bachert, 2024, British journal of clinical pharmacology.